Smith TJ - Search Results

1

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Nowakowski A, et al. Among authors: smith tj, smith la. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50. doi: 10.1073/pnas.172229899. Epub 2002 Aug 12. Proc Natl Acad Sci U S A. 2002. PMID: 12177434 Free PMC article.

2

Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Amersdorfer P, et al. Infect Immun. 1997 Sep;65(9):3743-52. doi: 10.1128/iai.65.9.3743-3752.1997. Infect Immun. 1997. PMID: 9284147 Free PMC article.

3

Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.

Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith T, Smith LA, Meagher MM. Potter KJ, et al. Protein Expr Purif. 1998 Aug;13(3):357-65. doi: 10.1006/prep.1998.0910. Protein Expr Purif. 1998. PMID: 9693060

4

Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Byrne MP, Smith TJ, Montgomery VA, Smith LA. Byrne MP, et al. Among authors: smith tj, smith la. Infect Immun. 1998 Oct;66(10):4817-22. doi: 10.1128/IAI.66.10.4817-4822.1998. Infect Immun. 1998. PMID: 9746584 Free PMC article.

5

Comparison of in vivo and in vitro mouse bioassays for botulinum toxin antagonists.

Sheridan RE, Deshpande SS, Smith T. Sheridan RE, et al. J Appl Toxicol. 1999 Dec;19 Suppl 1:S29-33. doi: 10.1002/(sici)1099-1263(199912)19:1+3.3.co;2-t. J Appl Toxicol. 1999. PMID: 10594897

6

Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.

Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T. Sheridan RE, et al. Toxicon. 2001 May;39(5):651-7. doi: 10.1016/s0041-0101(00)00189-6. Toxicon. 2001. PMID: 11072043

7

Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.

Marvaud JC, Smith T, Hale ML, Popoff MR, Smith LA, Stiles BG. Marvaud JC, et al. Infect Immun. 2001 Apr;69(4):2435-41. doi: 10.1128/IAI.69.4.2435-2441.2001. Infect Immun. 2001. PMID: 11254604 Free PMC article.

8

Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.

Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Amersdorfer P, et al. Vaccine. 2002 Feb 22;20(11-12):1640-8. doi: 10.1016/s0264-410x(01)00482-0. Vaccine. 2002. PMID: 11858873

9

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.

Jensen MJ, Smith TJ, Ahmed SA, Smith LA. Jensen MJ, et al. Among authors: smith tj, smith la. Toxicon. 2003 May;41(6):691-701. doi: 10.1016/s0041-0101(03)00042-4. Toxicon. 2003. PMID: 12727273

10

Roads from vaccines to therapies.

Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ. Smith LA, et al. Among authors: smith tj. Mov Disord. 2004 Mar;19 Suppl 8:S48-52. doi: 10.1002/mds.20009. Mov Disord. 2004. PMID: 15027054

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,767 results

Search Page

Filters